Literature DB >> 35015148

Integrative omics analysis identifies biomarkers of idiopathic pulmonary fibrosis.

Peiyan Zheng1, Shixue Sun1,2, Jingxian Wang3, Xiaohua Douglas Zhang4, Baoqing Sun5, Zhangkai Jason Cheng1, Kuan Cheok Lei2, Mingshan Xue1, Teng Zhang2, Huimin Huang1.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by chronic progressive pulmonary fibrosis and a poor prognosis. Genetic studies, including transcriptomic and proteomics, have provided new insight into revealing mechanisms of IPF. Herein we provided a novel strategy to identify biomarkers by integrative analysis of transcriptomic and proteomic profiles of IPF patients. We examined the landscape of IPF patients' gene expression in the transcription and translation phases and investigated the expression and functions of two new potential biomarkers. Differentially expressed (DE) mRNAs were mainly enriched in pathways associated with immune system activities and inflammatory responses, while DE proteins are related to extracellular matrix production and wound repair. The upregulated genes in both phases are associated with wound repair and cell differentiation, while the downregulated genes in both phases are associated with reduced immune activities and the damage of the alveolar tissues. On this basis, we identified thirteen potential marker genes. Among them, we validated the expression changes of butyrophilin-like 9 (BTNL9) and plasmolipin (PLLP) and investigated their functional pathways in the IPF mechanism. Both genes are downregulated in the tissues of IPF patients and Bleomycin-induced mice, and co-expression analysis indicates that they have a protective effect by inhibiting extracellular matrix production and promoting wound repair in alveolar epithelial cells.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  AEC injury; Immune responses; Multi-omics analysis; Myofibroblast proliferation; Whole-genome expression

Mesh:

Substances:

Year:  2022        PMID: 35015148     DOI: 10.1007/s00018-021-04094-0

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  70 in total

1.  The genetic basis of idiopathic pulmonary fibrosis.

Authors:  Jonathan A Kropski; Timothy S Blackwell; James E Loyd
Journal:  Eur Respir J       Date:  2015-04-02       Impact factor: 16.671

2.  Transcriptomic evidence of immune activation in macroscopically normal-appearing and scarred lung tissues in idiopathic pulmonary fibrosis.

Authors:  Irina G Luzina; Mariah V Salcedo; Mónica L Rojas-Peña; Anne E Wyman; Jeffrey R Galvin; Ashutosh Sachdeva; Andrew Clerman; June Kim; Teri J Franks; Edward J Britt; Jeffrey D Hasday; Si M Pham; Allen P Burke; Nevins W Todd; Sergei P Atamas
Journal:  Cell Immunol       Date:  2018-01-03       Impact factor: 4.868

3.  Comparative proteomic analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and lung transplant donor lungs.

Authors:  Martina Korfei; Sigrid Schmitt; Clemens Ruppert; Ingrid Henneke; Philipp Markart; Benjamin Loeh; Poornima Mahavadi; Malgorzata Wygrecka; Walter Klepetko; Ludger Fink; Philippe Bonniaud; Klaus T Preissner; Günter Lochnit; Liliana Schaefer; Werner Seeger; Andreas Guenther
Journal:  J Proteome Res       Date:  2011-03-29       Impact factor: 4.466

4.  Quantitative proteomics of bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis.

Authors:  Matthew W Foster; Lake D Morrison; Jamie L Todd; Laurie D Snyder; J Will Thompson; Erik J Soderblom; Kelly Plonk; Kent J Weinhold; Robert Townsend; Anne Minnich; M Arthur Moseley
Journal:  J Proteome Res       Date:  2015-01-14       Impact factor: 4.466

5.  Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF.

Authors:  W E Lawson; S W Grant; V Ambrosini; K E Womble; E P Dawson; K B Lane; C Markin; E Renzoni; P Lympany; A Q Thomas; J Roldan; T A Scott; T S Blackwell; J A Phillips; J E Loyd; R M du Bois
Journal:  Thorax       Date:  2004-11       Impact factor: 9.139

6.  Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer.

Authors:  Yongyu Wang; Phillip J Kuan; Chao Xing; Jennifer T Cronkhite; Fernando Torres; Randall L Rosenblatt; J Michael DiMaio; Lisa N Kinch; Nick V Grishin; Christine Kim Garcia
Journal:  Am J Hum Genet       Date:  2008-12-18       Impact factor: 11.025

7.  iTRAQ-Based Proteomics Reveals Novel Biomarkers for Idiopathic Pulmonary Fibrosis.

Authors:  Rui Niu; Ying Liu; Ying Zhang; Yuan Zhang; Hui Wang; Yongbin Wang; Wei Wang; Xiaohui Li
Journal:  PLoS One       Date:  2017-01-25       Impact factor: 3.240

8.  The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes.

Authors:  David N O'Dwyer; Katy C Norman; Meng Xia; Yong Huang; Stephen J Gurczynski; Shanna L Ashley; Eric S White; Kevin R Flaherty; Fernando J Martinez; Susan Murray; Imre Noth; Kelly B Arnold; Bethany B Moore
Journal:  Sci Rep       Date:  2017-04-25       Impact factor: 4.379

9.  Quantitative proteomic characterization of lung tissue in idiopathic pulmonary fibrosis.

Authors:  Yaqiong Tian; Hui Li; Yujuan Gao; Chuanmei Liu; Ting Qiu; Hongyan Wu; Mengshu Cao; Yingwei Zhang; Hui Ding; Jingyu Chen; Hourong Cai
Journal:  Clin Proteomics       Date:  2019-02-06       Impact factor: 3.988

10.  Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy.

Authors:  Claudia Landi; Laura Bergantini; Paolo Cameli; Miriana d'Alessandro; Alfonso Carleo; Enxhi Shaba; Paola Rottoli; Luca Bini; Elena Bargagli
Journal:  Sci Rep       Date:  2020-06-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.